To reach the next value inflection
LicenseRx asset brief
A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells
Probability of Success
15% · grade C · Medium data confidence
Model PoS 15% (grade C, medium data confidence). Strongest signals: IP position, Indication pull. Biggest drag: Competitive whitespace.
Data maturity (22%)
40
Early / Discovery; clinical reference.
IP position (16%)
88
Issued/granted patent on record.
Modality feasibility (14%)
55
Cell/gene therapy -- high upside, heavy manufacturing and regulatory load.
Indication pull (14%)
82
Oncology -- active buyer appetite.
Competitive whitespace (12%)
60
Crowded oncology field.
Translational evidence (12%)
62
Public evidence mentions: clinical, patient.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →